Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
Introduction
Urinary tract infections (UTIs) including cystitis and pyelonephritis are common both in community and hospital settings [1], [2], [3], [4], [5], [6]. The bacterial aetiology of UTIs is well established, with Escherichia coli being the predominant pathogen [2], [7], [8], [9], [10], [11], although other organisms gain greater importance in patients with complicated UTI [12], [13]. The guidelines of the Infectious Diseases Society of America recommend that uncomplicated UTIs should be treated empirically with sulphamethoxazole/trimethoprim (SMX/TMP) unless resistance rates of community-acquired E. coli to this agent exceed 10–20%, in which case a fluoroquinolone should be used [14]. Resistance of E. coli and other Enterobacteriaceae, however, has continued to evolve, with decreasing susceptibility to first-line agents such as ampicillin, nitrofurantoin, SMX/TMP and, more recently, the fluoroquinolones such as ciprofloxacin and levofloxacin [7], [8], [9], [10], [11], [12], [13], [15], [16], [17], [18], [19], [20]. As antibiotic therapy for uncomplicated UTIs is initiated empirically, antibiotic resistance profiles at the local, national and international levels must be known.
The goal of the North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study was to determine antibiotic susceptibility to commonly used first-line antibiotics in outpatient urinary isolates obtained from various geographic regions in the USA and Canada.
Section snippets
Isolate collection
NAUTICA is a UTI surveillance study involving 41 medical centres (30 from the USA and 11 from Canada). The majority of geographic regions of both the USA and Canada were represented (Appendix A Participating US investigators/sites, Appendix B Participating Canadian investigators/sites). From April 2003 to June 2004 inclusive, each centre submitted up to 50 consecutive outpatient midstream urine isolates. All isolates were deemed significant urinary tract pathogens by individual laboratory
Patient demographics
The demographics of the patients from whom the outpatient urinary isolates were obtained are described in Table 1. The mean age was 48.3 years (range 1 month to 99 years). Women in the 15–50-year-old group represented 39.3% of the isolates, whilst 34.1% of isolates were obtained from men and women ≥65 years of age. Isolates obtained from the USA represented 75.1% of all strains and Canadian strains represented 24.9% of all isolates collected.
Bacteriology of outpatient urinary isolates
The bacteriology of the 1990 outpatient urinary
Discussion
NAUTICA is an ongoing North American surveillance study assessing antibiotic resistance rates to commonly used agents in outpatient urinary tract pathogens. Although data were obtained from children ≤14 years of age as well as post-menopausal women 51–64 years of age, the majority of isolates obtained in this study were from pre-menopausal women (38.3% of all isolates) and elderly (≥65 years) females (20.1% of all isolates) (Table 1). In addition, the urinary isolates came primarily from the
Acknowledgments
This study was supported in part by the University of Manitoba, Procter & Gamble Inc. and Ortho-McNeil. Dr Ayman Noreddin is supported by an ACCP/Aventis Postdoctoral Fellowship. The authors thank M. Tarka for expert secretarial support.
References (32)
- et al.
Urinary tract infection in adults: research priorities and strategies
Int J Antimicrob Agents
(2001) Resistance trends in urinary tract pathogens and impact on management
J Urol
(2002)- et al.
Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999
Int J Antimicrob Agents
(2001) - et al.
The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women
Int J Antimicrob Agents
(1999) Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection
Int J Antimicrob Agents
(2003)- et al.
A randomized trial of short-course ciprofloxacin, ofloxacin, and trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group
Am J Med
(1999) - et al.
Outcomes associated with trimethoprim/sulfamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community acquired UTI
Int J Antimicrob Agents
(2002) - et al.
National patterns in the treatment of urinary tract infections in women by ambulatory care physicians
Arch Intern Med
(2002) Epidemiology of urinary tract infection
Infect Med
(2001)Resistant pathogens in urinary tract infections
J Am Geriatr Soc
(2002)
Urinary tract infection: traditional pharmacologic therapies
Am J Med
Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis
Clin Infect Dis
Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States
Antimicrob Agents Chemother
Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin
Clin Infect Dis
A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim–sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group
Antimicrob Agents Chemother
Cited by (169)
Escherichia coli urinary tract infections: Host age-related differences in bacterial virulence factors and antimicrobial susceptibility
2022, Journal of Microbiology, Immunology and InfectionHigh incidence of abnormal imaging findings in circumcised boys diagnosed with urinary tract infections
2020, Journal of Pediatric UrologyCitation Excerpt :Proteus is a relatively rare isolate in urine cultures in infants. The North American Urinary Tract Infection Collaborative Alliance showed that E. coli makes up approximately 57.5% of all outpatient isolates, with Proteus making up only 5.4% [15]. Studies have shown that E. coli is the predominant urinary tract pathogen in children under the age of 12 months, making up approximately 93% of UTIs presenting through the ED in a similar cohort [16].
Diagnosis and treatment of urinary tract infections across age groups
2018, American Journal of Obstetrics and GynecologyGlobal research output in antimicrobial resistance among uropathogens: A bibliometric analysis (2002–2016)
2018, Journal of Global Antimicrobial Resistance